BACKGROUND Gestational Diabetes Mellitus (GDM), described as glucose intolerance first recognized during pregnancy is usually diagnosed after screening at 24-28 weeks of gestation after the onset of the condition. Effective early identification of high-risk group and screening at an earlier time could improve pregnancy outcomes. Insulin resistance increases throughout the 2 nd and 3 rd trimester whereas the fat mass of the individual starts increasing from first trimester itself. The concentration of visfatin, an insulinomimetic and a novel adipocytokine is found to correlate with intra-abdominal adipose tissue and is found to be increased in cases of GDM. This change in visfatin levels can occur from the first trimester in response to adipose tissue remodelling and increased insulin resistance. We wanted to determine levels of visfatin in the first trimester of normal pregnancies and those who developed GDM later on during the pregnancy. The relationship between visfatin and parameters of glucose metabolism were also investigated. METHODS 84 primis between 11-13 weeks of gestation were randomly selected. BMI, concentration of plasma glucose, serum insulin, insulin resistance and serum visfatin were estimated. The participants of the study were followed up till 24-28 weeks of gestation and screened for GDM. Of the study population 17 women were diagnosed to have GDM and were treated as the case group. Means from both groups were analysed by Mann Whitney U test. The magnitude of correlations was determined by Pearson's correlation coefficient. p Value of <0.05 was considered as statistically significant. RESULTS BMI, fasting plasma glucose (first trimester), fasting serum insulin, HOMA-IR and serum visfatin were all significantly higher in the GDM group than in the control group. There were no statistically significant correlations between visfatin and any of the indicators. CONCLUSIONS Pregnant women with higher visfatin levels at first trimester have higher levels of insulin resistance and are more likely to develop GDM independent of glycaemic status and adiposity. The increased levels of visfatin in the first trimester might be related to the development and progression of GDM.
Obesity, broadly refers to increased body fat, which has become an important public health problem. Its prevalence continues to increase worldwide. In the World Health Survey, the prevalence of physical inactivity in India was 9.3% in men and 15.2% in women. Adipose tissue being an endocrine organ secretes several cytokines such as Interleukin-6, TNF-α and adipokines such as adiponectin, hepcidin, resistin. This study is to compare ferritin to iron and hepcidin with normal and obese men. This case-control study was conducted at a multispecialty centre in Chennai, Tamil Nadu between 2013 and 2015, including 80 subjects of South Indian population. The biochemical parameters which were measured included the levels of hepcidin, ferritin, iron, Total Iron Binding Capacity and Hemoglobin. The results were statistically analyzed. Mann whitney U test performed to check for the statistical significance for differences in mean between the groups. The mean hepcidin values for the control group was 800.55 ± 503.50 and the study group was 1106.68 ± 826.25 and was found to be statistically significant with a p-value of 0.03. There was positive correlation of hepcidin with ferritin and Transferrin Saturation. Hepcidin is recognized as the key regulator of systemic iron homeostasis. The measurement of hepcidin in biological fluids is therefore a promising tool in the diagnosis and management of medical conditions in which iron metabolism is affected.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.